Cannabigerolic Acid (CBG-a) Cannabinoid Research

Cannabigerolic Acid (CBG-a) Research Dashboard

5

Primary Studies

2

Related Studies

7

Total Studies

Clinical Studies

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

0

Meta-analyses/Reviews

1

Animal studies

3

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 7 studies associated with Cannabigerolic Acid (CBG-a).

Here is a small sampling of Cannabigerolic Acid (CBG-a) studies by title:


Components of the Cannabigerolic Acid (CBG-a) Research Dashboard

  • Top medical conditions associated with Cannabigerolic Acid (CBG-a)
  • Proven effects in clinical trials for Cannabigerolic Acid (CBG-a)
  • Receptors associated with Cannabigerolic Acid (CBG-a)
  • Individual study details for Cannabigerolic Acid (CBG-a)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Cannabigerolic Acid (CBG-a)

Description of Cannabigerolic Acid (CBG-a)

The plant-based (phytocannabinoid) Cannabigerolic-acid was discovered in 1965. It is the essential precursor to all other phytocannabinoids such as THC-A, CBD-A, CBG-A for example.

Other Names:

Cannabigerolic Acid

Cannabigerolic Acid (CBG-a) Properties and Effects

Antileishmanial, Neuroprotective

Cannabigerolic Acid (CBG-a) Receptor Binding

Weak affinity for CB1 (Ki 440 nM). Weak affinity for CB2 (Ki 337 nM).

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.